Roche Holding AG is weighing direct-to-patient drug sales in the US, bypassing the middleman for its pricey medicines for ...

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

Trump has signed an executive order proposing a “Most Favoured Nation” drug pricing policy, which would insist that ...

Roche reported better than expected first-half operating profit, driven by strong sales of breast cancer and asthma ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

Roche (RHHBY) plans direct-to-patient drug sales in the U.S. to avoid the influence from pharmacy benefit managers in product ...

Roche is in talks with the US government to cut out the pharmaceutical industry’s intermediaries and sell medicines directly to patients, as drugmakers try to see off the threat of dramatic price cuts ...

Roche obtained CT-173, a PYY mimetic, in its $2.7 billion acquisition of Carmot Therapeutics in December 2023. The company ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was longer than usual on our side of the pond, thanks to a holiday — was relaxing and invigorating.

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had potential to tackle a common superbug that has become resistant to other ...

The last new class of antibiotics approved to treat Gram-negative bacteria was in 1968. Roche will launch a Phase 3 trial for zosurabalpin at the end of the year, or early next year.